BioHarvest Sciences (BHST) Announces Strategic CDMO Agreement With Saffron Tech

BioHarvest Sciences Inc. (NASDAQ:BHST) is one of the best consumer defensive stocks with more than 50% upside. On October 30, BioHarvest Sciences Inc. (NASDAQ:BHST) announced a strategic CDMO agreement with Saffron Tech for the development and commercialization of saffron-derived botanical compounds by employing BioHarvest’s patented Botanical Synthesis platform, which allows “consistent, scalable, and cost-effective production of plant-based molecules without growing the plant itself”. Saffron Tech pioneers “advanced cultivation methods” for saffron, which is one of the most valued and health-promoting botanicals in the world.

According to the terms of the agreement, 75% of the developed saffron compositions, ownership IP, and commercial associated rights would be owned by Saffron Tech, while the remaining 25% will be held by BioHarvest Sciences Inc. (NASDAQ:BHST).

BioHarvest Sciences Inc. (NASDAQ:BHST) also announced that it aims to manufacture the compound at large scale upon the completion of the composition’s development phases, while also marketing it in its direct-to-consumer e-commerce business through the development of “a line of nutraceutical products leveraging saffron’s functional benefits”, including eye health, cognitive functions, and antioxidant benefits.

BioHarvest Sciences Inc. (NASDAQ:BHST) offers nutraceutical health and wellness products, including dietary supplements.

While we acknowledge the potential of BHST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.